

Rev01
 Update: Apr,07,2025

DATASHEET

TPM1, His, Human

Cat. No.: Z05909

Product Introduction

| | |
|-------------------------------------|--|
| Species | Human |
| Protein Construction | <div> <div>His</div> <div>TPM1 (Met1-Met284)_x000D_</div> <div>Accession # NP_000357.3</div> </div> <div> <div>N-term</div> <div>C-term</div> </div> |
| Purity | > 95% as determined by BisTris PAGE > 90% as determined by HPLC |
| Endotoxin Level | Less than 1EU per µg by the LAL method. |
| Expression System | E.coli |
| Theoretical Molecular Weight | 34.26 kDa |
| Apparent Molecular Weight | The protein has a predicted MW of 34.26 kDa same as Bis-Tris PAGE result. |
| Formulation | Lyophilized from 0.22µm filtered solution in PBS, 150mM NaCl (pH 7.4). |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |

Background

Target Background : Tropomyosin-1 (TPM1), a widely expressed actin-binding protein, is downregulated in many tumors and associated with cancer progression. TPM1 overexpression in RCC cell lines can induce tumor cell apoptosis via the p53-mediated mitochondrial pathway. Further studies are needed to fully elucidate the potential of TPM1 as a candidate for RCC targeted therapy in the future.

Synonyms : C15orf13; TMSA; CMD1Y; CMH3; HTM-alpha; LVNC9

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China

GenScript USA, Inc.

860 Centennial Ave. Piscataway, NJ 08854

Tel: 1-732-885-9188